Brolucizumab – EURETINA

2021 Virtual

Novartis: Learnings from the clinic: management of IOI-related events associated with brolucizumab – Learnings from the clinic: management of IOI-related events associated with brolucizumab

Presenter: Arshad Khanani

2021 Virtual

Novartis: Learnings from the clinic: management of IOI-related events associated with brolucizumab – Live discussion with Q&A

Presenter: Arshad Khanani

2021 Virtual

Prize Papers 9: AMD III – Long-term efficacy outcomes with Brolucizumab vs Aflibercept treatment in patients with early residual fluid presence in nAMD: post hoc analysis of pooled data from HAWK & HARRIER studies

Presenter: Richard Gale

2021 Virtual

Novartis: Response to brolucizumab in a real-world setting – Response to brolucizumab in a real-world setting

Presenter: Justus Garweg

Video

Novartis: Response to brolucizumab in a real-world setting – Live discussion with Q&A

Presenter: Justus Garweg

Video

EURETINA Session 13: Retinal Vascular Diseases – Occlusive retinal vasculitis following intravitreal brolucizumab for exudative age-related macular degeneration

Presenter: Jeffrey Heier

2021 Abstracts

A national framework for implementing Beovu (brolucizumab) in the treatment of patients with neovascular age-related macular degeneration: An expert consensus of a UK steering committee

Author: Ian Pearce (United Kingdom)

Co-authors: On behalf of the steering committee .

2021 Abstracts

Structural and vascular features in non-responder neovascular age-related macular degeneration after Brolucizumab injection: An optical coherence tomography angiography study

Author: Federica Fossataro (Italy)

Co-authors: Mariano Cozzi, Giulio Maione, Alfredo Pece

2021 Abstracts

Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KESTREL and KITE Phase III studies

Author: Ramin Tadayoni (France)

Co-authors: David Brown, Sebastian Wolf, Francesco Bandello, Andres Emanuelli, Jose Juan Escobar Barranco, Joao Figueira

2021 Abstracts

Comparative assessment of the maximum thickness of pigment epithelial detachments and sub-RPE fluid in patients treated with Brolucizumab versus Aflibercept in the HAWK & HARRIER studies

Author: Arshad Khanani (United States)

Co-authors: Srinivas R. Sadda, David Sarraf, Ramin Tadayoni, David T. Wong, Anne-Sophie Kempf, Insaf Saffar

2021 Abstracts

Long-term efficacy outcomes with Brolucizumab vs Aflibercept treatment in patients with early residual fluid presence in nAMD: post hoc analysis of pooled data from HAWK & HARRIER studies

Author: Richard Gale (United Kingdom)

Co-authors: Rishi Singh, Chirag Jhaveri, Charles C. Wykoff, Giovanni Staurenghi, Tomohiro Iida, Adrian Koh

2021 Abstracts

Early experience of Brolucizumab use in a tertiary hospital setting for neovascular age-related macular degeneration (nAMD)

Author: Cristina Cristian (United Kingdom)

Co-authors: Aditi Mohla, Martin McKibbin, Rajarshi Mukherjee

2021 Abstracts

Brolucizumab q16w/q12w dosing allocation in nAMD: a post hoc evaluation of data from the HAWK and HARRIER studies

Author: Michael Singer (United States)

Co-authors: Arshad M. Khanani, Armin Wolf, Rita Flores, Jay Chhablani, Guruprasad B, Andreas Clemens

2021 Abstracts

Short-term efficacy and safety outcomes of Brolucizumab in the real-life clinical practice

Author: Chiara Maria Eandi (Italy)

Co-authors: Andrea Montesel, Chiara Maria Eandi

2021 Abstracts

Intravitreal Brolucizumab for treatment of refractory macula edema due to neovascular age-related macular degeneration (real life data)

Author: Alaa Din Abdin (Germany)

Co-authors: Wissam Aljundi, Isabel Weinstein, Khalil Aljawhari, Shady Suffo, Berthold Seitz